JNJ
The cancer machine keeps humming
Johnson & Johnson’s oncology business isn’t just growing — it’s still acting like the company’s best plug-in battery. In Q1, Darzalex and newer launches helped push oncology sales up 17.8%, which is the kind of number that makes a big pharma CFO smile without trying too hard.
Why investors should care
The headline here isn’t just one good quarter. It’s that J&J is showing it can keep squeezing growth out of its cancer franchise while also layering in new products. That matters because oncology is one of the clearest ways for J&J to offset slower growth elsewhere and keep the market believing in its long-term compounding story.
The long game is the real story
Management is still targeting $50 billion in cancer sales by 2030, which is basically J&J saying: “Yes, we’d like a very large chunk of the oncology pie, thank you.” If Darzalex and the newer launches keep doing their thing, that goal starts looking less like corporate wishcasting and more like a roadmap.
Big picture
For investors, this is the familiar but important J&J trade: not flashy, not meme-stock chaotic, just a giant healthcare machine quietly trying to keep its growth engines warm. And right now, oncology is doing the heavy lifting.